Holen Sie sich die Stockscreener-App
77.18
3.44%
2.57
Schlusskurs vom Vortag:
$74.61
Offen:
$74.91
24-Stunden-Volumen:
653.32K
Relative Volume:
1.10
Marktkapitalisierung:
$5.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-19.79
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+5.02%
1M Leistung:
-0.36%
6M Leistung:
-18.13%
1J Leistung:
+17.62%
1-Tages-Spanne:
$72.69
$77.50
1-Wochen-Bereich:
$70.25
$77.50
52-Wochen-Spanne:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
77.18 | 5.19B | 0 | -224.29M | -185.06M | -3.90 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent, Inc. Reports Q1 2025 Financial Results - TipRanks
Nuveen Asset Management LLC Has $6.62 Million Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium - The Globe and Mail
Nuvalent (NUVL) Stock on the Rise: Decoding the 4.7% Surge and Price Potential - Daily Chhattisgarh News
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year - Investing.com Australia
Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Dimensional Fund Advisors LP - Defense World
A Bullish 2025 Outlook For Nuvalent Inc (NASDAQ: NUVL) Shares - Stocksregister
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent (NUVL) Targets Key Milestones with Solid Financial Backing | NUVL Stock News - GuruFocus
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - PR Newswire
Financial Health Check: Examining Nuvalent Inc (NUVL)’s Key Ratios - DWinneX
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Lowered by Envestnet Asset Management Inc. - Defense World
When the Price of (NUVL) Talks, People Listen - news.stocktradersdaily.com
Nuvalent Inc (NUVL) looking to reclaim success with recent performance - Sete News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results - Seeking Alpha
Nuvalent reveals preclinical data on cancer drug zidesamtinib - Investing.com
Nuvalent Announces Publication in Molecular Cancer Therapeutics - GuruFocus
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Nuvalent, Inc. (NASDAQ:NUVL) Position Boosted by Wells Fargo & Company MN - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - ADVFN
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors - BioWorld MedTech
UBS gives a Buy recommendation for Nuvalent Inc (NUVL) - knoxdaily.com
JPMorgan Chase & Co. Acquires 47,818 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Trend Tracker for (NUVL) - news.stocktradersdaily.com
Nuvalent Board Member Resigns, Joins Advisory Board - TipRanks
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent (NUVL) Gets a Buy from Barclays - The Globe and Mail
Nuvalent: Cannot Make Sense Of The Valuation - Seeking Alpha
Nuvalent stock touches 52-week low at $61.75 amid market shifts By Investing.com - Investing.com South Africa
Nuvalent stock touches 52-week low at $61.75 amid market shifts - Investing.com Australia
Norges Bank Invests $24.95 Million in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
KLP Kapitalforvaltning AS Buys New Shares in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib - Onco'Zine
Commit To Purchase Nuvalent At $55, Earn 11.9% Annualized Using Options - Nasdaq
(NUVL) On The My Stocks Page - news.stocktradersdaily.com
Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? - Yahoo
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Quantisnow
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Stake Cut by Virtu Financial LLC - MarketBeat
Teacher Retirement System of Texas Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):